Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
muzolimine
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Muzolimine is a small molecule, pyrazole-based high-ceiling loop diuretic that was used for the treatment of hypertension and kidney failure. It acts primarily by inhibiting sodium-potassium-chloride cotransporter (Na+K+Cl-) in the thick ascending limb of Henle’s loop, leading to increased excretion of sodium and water (diuresis). Muzolimine is considered to act as a prodrug; its active metabolite is secreted into the tubular lumen via a probenecid-sensitive pathway and inhibits Na+K+Cl- cotransport. The drug was withdrawn worldwide due to severe neurological side effects[1][3][4][5][6][7].
- Brand names
- Edrul
- Other names
- muzolimina55294-15-0
02
Targets
NKCC2 (Sodium-potassium-chloride cotransporter 2)NKCC (Sodium-potassium-chloride cotransporter)
Beyond the preview
Go deeper on muzolimine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on muzolimine.